Swedish Spermosens’ vision is to improve diagnostics within the area of male infertility and thus help improve IVF treatments. Using the company’s JUNO-Checked system...

For Solna-based Promore Pharma, 2022 was characterised by steady advancement in the development of its drug candidate ensereptide. During the year, the company carried...

2022 was a tough year for many life science investors, who not only witnessed several drops, but also sharp drops in the value of...

Recently, attention has again been focused on ALS. The fatal neurological disease has long been one of the biggest medical mysteries. Today, the knowledge...

As the societal burden of Alzheimer’s disease continues to grow, drug development in the field has struggled to keep up the pace. A huge...

Biotech company Abliva is now preparing for the perhaps biggest step in the company's history to date – a pivotal phase II/III study with...

Biopharmaceutical company Lipum is approaching clinical studies with the candidate SOL-116, which targets chronic inflammatory diseases such as rheumatoid arthritis. CEO Einar Pontén presented the...

For known reasons, it has been a rough first half of the year for the stock market. Several of the world's leading indices lost...

The most important activity for Promore Pharma in 2022 has been the phase IIa study with drug candidate ensereptide. The company announced earlier this...

Ever since their discovery more than 200 years ago, vaccines have helped revolutionise healthcare, especially when it comes to combatting deadly infectious diseases. As...